Internal Medicine, Pulmonary Disease · Miami, FL
NPI
1437448271
Since 2011
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
78 SW 13th Ave Ste 202
Miami, FL, 33135
Phone (305) 545-5353
Groups this clinician bills Medicare through
Medicare paid, 2024
$39K
755 services
Medicare patients, 2024
107
Average age 76
Drug cost, 2024
$3.1M
9,963 prescriptions
Company payments, 2025
$12K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Yoel Brito was code 99214 (office e&m - established), 131 times for 50 patients. In total Yoel Brito billed 755 services in 26 codes, and Medicare paid $39K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-07-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 131 | 50 | $105.11 | $14K |
| 94664 E&M - Miscellaneous | Office | 129 | 53 | $15.16 | $1,955 |
| 94640 Treatment - Miscellaneous | Office | 77 | 48 | $6.77 | $521 |
| 94618 Pulmonary Function Testing | Office | 68 | 48 | $27.16 | $1,847 |
| 94060 Pulmonary Function Testing | Office | 67 | 47 | $30.83 | $2,066 |
| 94726 Pulmonary Function Testing | Office | 67 | 47 | $45.01 | $3,015 |
| 94729 Pulmonary Function Testing | Office | 67 | 47 | $45.91 | $3,076 |
| 99223 Hospital E&M - Initial | Facility | 50 | 46 | $144.77 | $7,238 |
| G0296 Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | Office | 17 | 16 | $28.71 | $488 |
By year: 2022 $83K for 1,314 services; 2023 $53K for 1,030 services; 2024 $39K for 755 services.
Medicare prescription drug claims, 2024
In 2024, the drug Yoel Brito prescribed most often to Medicare patients was Albuterol Sulfate Hfa (Albuterol Sulfate), with 2,145 prescriptions and refills. In total Yoel Brito wrote 9,963 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | 2,145 | 2,328 | 532 | $58K |
| Montelukast Sodium Generic | 1,604 | 2,894 | 434 | $8,404 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 1,377 | 1,507 | 270 | $952K |
| Fluticasone Propionate Generic | 1,012 | 1,523 | 296 | $11K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 1,007 | 1,112 | 233 | $686K |
| Ventolin Hfa Albuterol Sulfate | 504 | 516 | 143 | $28K |
| Azelastine Hcl Generic | 258 | 390 | 82 | $6,256 |
| Symbicort Budesonide/Formoterol Fumarate | 237 | 282 | 91 | $62K |
| Prednisone Generic | 230 | 265 | 154 | $382 |
| Azithromycin Generic | 170 | 176 | 136 | $461 |
| Atrovent Hfa Ipratropium Bromide | 151 | 154 | 44 | $72K |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 141 | 155 | 43 | $24K |
| Breyna Budesonide/Formoterol Fumarate | 132 | 149 | 43 | $17K |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 129 | 139 | 29 | $65K |
| Roflumilast Generic | 112 | 146 | 28 | $6,900 |
Brand drugs: 5,846 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Yoel Brito $12K ($12K in general payments such as food, travel and fees) from 19 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $9,340.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 40 | $9,340 |
| GlaxoSmithKline, LLC. GSK | 27 | $580 |
| Verona Pharma, Inc. VRNA | 19 | $509 |
| Genzyme Corporation SNY | 14 | $359 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $208 |
| Insmed, Inc. INSM | 7 | $153 |
| Amgen Inc. AMGN | 5 | $135 |
| Viatris Specialty LLC | 3 | $93.05 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $78.99 |
| Grifols USA, LLC | 2 | $61.94 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.